Drug General Information (ID: DDI7NSZV62)
Drug Name			Perflutren		Drug Info		Amisulpride		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Ultrasound Contrast Media				Antipsychotic Agents
Structure

Mechanism of Perflutren-Amisulpride Interaction (Severity Level: Major)
Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph
Drug Name		Perflutren				Amisulpride
Mechanism		Prolong QT interval				Prolong QT interval
Key Mechanism Factor 1
		Factor Name		QT interval
		Factor Description		Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death.
Mechanism Description		Increased risk of prolong QT interval by the combination of Perflutren and Amisulpride

Recommended Action
Management		Concomitant use of perflutren lipid microsphere suspension with other agents that can prolong the QT interval should be avoided in some cases. Please refer to the prescribing information for these drugs for more information. No data are available regarding the effect of perflutren protein-type A microsphere suspension (Optison) on the QT interval of the electrocardiogram.

References
1	Product Information. Definity (perflutren). Lantheus Medical Imaging Inc, North Billerica, MA.
2	Product Information. Optison (perflutren). Mallinckrodt Medical Inc, St. Louis, MO.